Among patients with #AtrialFibrillation, higher serum neurofilament light chain levels were associated with increased risk of major vascular events, stroke, cardiovascular death, and heart failure hospitalization.
#ACC2026 @ACCinTouch
https://ja.ma/4sDQPq5
In this podcast, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and Deputy Editor Preeti Malani, MD, MSJ, discuss the latest science published in JAMA:
➡️ US #Pediatric #Sepsis Estimates,
➡️ CMS #Oncology Care Model and #Medicare Payments,
➡️ Resistant #Hypertension Review, and more.
🎧 Listen now: https://ja.ma/4tfER66
📊 JAMA Clinical Guidelines Synopsis: The 2026 #PediatricSepsis guidelines by SCCM and ESICM recommend immediate antimicrobial therapy for suspected septic shock and timely blood lactate measurement for all children with sepsis.
https://ja.ma/4uY8wST
📊 JAMA Clinical Guidelines Synopsis: The newly released Surviving #Sepsis Campaign guidelines from ESICM and SCCM endorse early broad-spectrum antibiotics, rapid fluid resuscitation, and deescalation strategies for adults with sepsis or septic shock.
https://ja.ma/3NHStrD
#HepatitisB virus newborn vaccination rates in the US peaked at 83% in early 2023 but dropped to 73% by August 2025, coinciding with increased public discourse regarding childhood vaccination.
https://ja.ma/4sEAWjh
💬 Viewpoint: While restricting ultraprocessed foods from #SNAP may curb chronic disease and generate taxpayer savings, concerns persist about increased stigma, reduced food access, and impacts on poverty alleviation.
https://ja.ma/4caPwZP
Life-extending therapy in patients with diabetes but no known ASCVD
136 deaths (5-year KM estimate, 7.8%) in the evolocumab group vs 172 deaths (5-year KM estimate, 10.1%) in the placebo group
☠️ HR 0.76 [95% CI, 0.61-0.95]
@TIMIStudyGroup @kewatson @AnnMarieNavar @JAMACardio
R to @JAMACardio: Learn more about the JAMA Network’s activities at #ACC26:
https://ja.ma/4s3paOe
R to @JAMACardio: 💬 Editor's Note: In HFmrEF/HFpEF, modest clinical and biomarker declines precede sudden death, but similar patterns occur before other fatal outcomes, limiting risk prediction specificity.
https://ja.ma/4s2seKG
R to @JAMACardio: In #HFmrEF/#HFpEF, sudden death was usually preceded by modest worsening of symptoms, declining quality of life, and rising NT-proBNP, similar to other causes of death, limiting prediction specificity.
https://ja.ma/4s5GLVP
R to @JAMACardio: Biomarker-driven #HFpEF risk stratification using the EMPEROR-Preserved model identified higher absolute benefit from finerenone for patients at greatest baseline risk, while relative treatment effect remained uniform.
https://ja.ma/4sjg6oN
R to @JAMACardio: 💬 Editor's Note: Dual incretin therapy may improve cardiorenal outcomes when broader endpoints are considered, but robust superiority trials are needed for #Type2Diabetes.
https://ja.ma/3Q5OANN
R to @JAMACardio: In patients w/ type 2 #diabetes and #cardiovascular disease, the dual #GLP1/glucose-dependent insulinotropic polypeptide agonist #tirzepatide was associated w/va lower incidence of major cardiorenal events compared with dulaglutide.
https://ja.ma/3O6uAdl
R to @JAMACardio: 📊 Research Summary: Among adults with high-risk #diabetes and elevated LDL cholesterol but no significant atherosclerosis, adding evolocumab to statin therapy reduced first major cardiovascular events.
https://ja.ma/3PO6PHs
R to @JAMACardio: 💬 Editorial: In the VESALIUS-CV trial, evolocumab reduced major cardiovascular events in high-risk patients, including those with long-standing #diabetes, already receiving statins but not reaching LDL-C targets.
https://ja.ma/41xWfXK
🧵 #ACC26 attendees, check out these findings from today's JAMA and @JAMACardio presentations:
Among adults with high-risk #diabetes and elevated LDL cholesterol, evolocumab combined with statins reduced rates of major cardiovascular events compared to statin alone.
https://ja.ma/3O2hz4y
In a randomized trial of a PCSK9 inhibitor [for LDL cholesterol lowering] vs placebo for patients with diabetes and no known heart disease, there was significant reduction of major cardiovascular events including deaths
#ACC26 @JAMA_current
https://jamanetwork.com/journals/jama/fullarticle/2847162?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2026.3277
Among patients with #diabetes but without known significant atherosclerosis, intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event vs placebo in the VESALIUS-CV trial.
#ACC26 @ACCinTouch
🎥 Watch the video and read the full article:
https://ja.ma/4uXE0IC
The #PCSK9 inhibitor evolocumab ↘️ the risk of a first major CV event in patients w/ diabetes without known significant atherosclerosis, according to a prespecified subgroup analysis of the VESALIUS-CV trial, presented during a LBCT session at #ACC26. 🔗 https://bit.ly/3PBZqLo
📊 Research Summary: Among adults with high-risk #diabetes and elevated LDL cholesterol but no significant atherosclerosis, adding evolocumab to statin therapy reduced first major cardiovascular events.
#ACC2026 @ACCinTouch
https://ja.ma/4bMwtDS
R to @JAMA_current: 💬 Editorial: In the VESALIUS-CV trial, evolocumab reduced major cardiovascular events in high-risk patients, including those with long-standing #diabetes, already receiving statins but not reaching LDL-C targets.
#ACC26 @ACCinTouch
https://ja.ma/3PzQC8Q
Among adults with high-risk #diabetes and elevated LDL cholesterol, evolocumab combined with statins reduced rates of major cardiovascular events compared to statin alone. 🧵
#ACC26 @ACCinTouch
https://ja.ma/4df4IX4
📍 At #ACC26? Attend the JAMA_current Late-Breaking Clinical Trials session:
📅 Mar 28 | 3:35 to 4:45 PM
📍 Main Tent, Great Hall
Chaired by JAMA Executive Editor Greg Curfman, MD
Biomarker-driven #HFpEF risk stratification using the EMPEROR-Preserved model identified higher absolute benefit from finerenone for patients at greatest baseline risk, while relative treatment effect remained uniform.
#ACC26 @ACCinTouch
https://ja.ma/48g2OSv
In #HFmrEF/#HFpEF, sudden death was usually preceded by modest worsening of symptoms, declining quality of life, and rising NT-proBNP, similar to other causes of death, limiting prediction specificity.
#ACC26 @ACCinTouch
https://ja.ma/4sBAbqZ
In patients w/ type 2 #diabetes and #cardiovascular disease, the dual #GLP1/glucose-dependent insulinotropic polypeptide agonist #tirzepatide was associated w/va lower incidence of major cardiorenal events compared with dulaglutide.
#ACC26 @ACCinTouch
https://ja.ma/4lYypxO
📚 DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh RCT.
From @JAMA_current
🔓 Free to read online during #ACC26
https://ja.ma/4sFl3ZX
📍 At #ACC26?
Join the Joint @ACCinTouch / JAMA Late‑Breaking Clinical Trials II session:
📅 Today, March 28
⏰ 3:45–4:45 PM CT
📍 Main Tent, Great Hall
Chaired by JAMA Executive Editor Greg Curfman, MD.
R to @JAMA_current: Learn more about the JAMA Network’s activities at #ACC26:
https://ja.ma/4rXxJKo
R to @JAMA_current: This secondary analysis of the CRHCP study suggests that intensive BP control was associated with reduced incidence of the composite cardiovascular disease outcome but not increased risk of kidney injury in patients without chronic kidney disease.
https://ja.ma/412Yan1
R to @JAMA_current: Among adults with HeFH who were already on statin therapy, treatment with enlicitide was well tolerated and reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a).
https://ja.ma/3PEOJaU
R to @JAMA_current: RCT: Patients with #AFib who continued their usual caffeinated coffee intake after cardioversion experienced less recurrence of AF or atrial flutter compared to those who abstained from coffee and caffeine.
https://ja.ma/3NRqSEr
📣 #ACC26 attendees: Explore JAMA Network’s collection of resources for ACC attendees. 🧵
RCT: Home-delivered, low-sodium Dietary Approaches to Stop Hypertension (DASH) groceries and dietitian support temporarily improved blood pressure and LDL cholesterol in Black adults with high BP versus monetary support.
https://ja.ma/4rYKAMi
Recent updates from @ACCinTouch and @American_Heart have changed US lipid guidelines for blood cholesterol and triglycerides management.
Jennifer Abbasi, Director of JAMA Medical News, and Associate Managing Editor Kate Schweitzer discuss practice-changing recommendations—including earlier cholesterol screening, new risk estimation tools, and updated goals for LDL-C and additional biomarkers like lipoprotein (a) and apolipoprotein B.
🎧 Listen now: https://ja.ma/48g0hrt
R to @JAMA_current: Learn more about the JAMA Network’s activities at #AAD2026:
https://ja.ma/3PLkoYb
R to @JAMA_current: This survey study found that Canadian adolescents have high sunburn prevalence and inconsistent sun protection, with elevated risk among older, female, higher-income, and Indigenous youths.
https://ja.ma/4sOBjHS
R to @JAMA_current: Agent Orange exposure was associated with increased risk of acral #melanoma among US veterans, supporting the need for research into environmental factors in melanoma risk.
https://ja.ma/4sz4mPD
R to @JAMA_current: Among patients with juvenile localized scleroderma, mycophenolate mofetil and methotrexate showed comparable efficacy, but mycophenolate mofetil had improved tolerability.
https://ja.ma/4sWykxv
R to @JAMA_current: A multi-phase qualitative study developed a staged patient decision aid for #AtopicDermatitis systemic treatment that balances simple patient-focused content and clinician-desired detail, supporting shared decision-making in adults.
https://ja.ma/4tcfTV5
📣 #AAD2026 attendees: Explore JAMA Network’s collection of resources for AAD attendees. 🧵
Nonmelanoma skin ##cancer, composed primarily of BCC and cSCC, is the most common cancer in the US, with an estimated 5.4 million diagnoses annually.
This Review summarizes the presentation, diagnosis, management, and prevention of #keratinocyte #carcinomas. https://ja.ma/47uTTwl